Vertex Pharmaceuticals Incorporated (VRTX)
Shareholders that lost money on Vertex Pharmaceuticals Incorporated (VRTX) should contact Levi & Korsinsky about Securities Fraud Investigation - VRTX
NEW YORK, NY / ACCESSWIRE / December 20, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex Pharmaceuticals Incorporated ("Vertex Pharmaceuticals") (NASDAQ:VRTX) concerning possible violations of federal securities laws. On December 19, 2024, the company reported disappointing results from its RewinD-LB Phase 2b clinical trial for the pain drug suzetrigine.
VRTX Down as Non-Opioid Drug Shows Similar Pain Reduction as Placebo
Vertex announces data from a phase II study evaluating its NaV1.8 pain signal inhibitor, suzetrigine, for treating painful lumbosacral radiculopathy. Shares down.
Vertex Pharmaceuticals Inc. (VRTX) Investors Who Have Lost Money Should Contact Block & Leviton to Find Out How They Might Recover Money Through The Firm's Investigation
BOSTON, MA / ACCESSWIRE / December 20, 2024 / Block & Leviton is investigating Vertex Pharmaceuticals Inc. (Nasdaq:VRTX) for potential securities law violations. Investors who have lost money in their Vertex Pharmaceuticals Inc. investment should contact the firm to learn more about how they might recover those losses.
Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It
Zacks.com users have recently been watching Vertex (VRTX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Why Vertex Pharmaceuticals (VRTX) Outpaced the Stock Market Today
Vertex Pharmaceuticals (VRTX) closed at $468.09 in the latest trading session, marking a +0.94% move from the prior day.
The Ultimate Biotech Stock to Buy With $500 Right Now
Investing in biotech stocks isn't for everyone because the very nature of their business is fraught with risk. As a result, biotech stocks can be highly volatile.
Vertex Pharmaceuticals (VRTX) Falls More Steeply Than Broader Market: What Investors Need to Know
In the most recent trading session, Vertex Pharmaceuticals (VRTX) closed at $469.29, indicating a -0.99% shift from the previous trading day.
Why Is Vertex (VRTX) Down 8.6% Since Last Earnings Report?
Vertex (VRTX) reported earnings 30 days ago. What's next for the stock?
Investors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here is What You Need to Know
Zacks.com users have recently been watching Vertex (VRTX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Got $500? 1 Biotech Stock to Buy and Hold Forever
Got $500? 1 Biotech Stock to Buy and Hold Forever
Buy Signal Flashing For Struggling Biotech
Biotech Vertex Pharmaceuticals (VRTX) has been struggling on the charts over the past few weeks, putting a dent in its now 10% year-to-date gain. The stock's 5.6% post-earnings pop earlier this month has already been erased, and VRTX is now trading at its lowest level since June.
Vertex Pharmaceuticals Incorporated (VRTX) Presents at Stifel 2024 Healthcare Conference (Transcript)
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX ) Stifel 2024 Healthcare Conference November 19, 2024 8:00 AM ET Company Participants Stuart Arbuckle - EVP, COO Conference Call Participants Paul Matteis - Stifel Paul Matteis Great, good morning. It's my pleasure to be moderating this chat with Stuart Arbuckle, COO of Vertex Pharmaceuticals.
